Biblio

Author Title [ Type

] Year

Filters: Author is Fleischhauer, Katharina [Clear All Filters]

Journal Article

Turki AT, Klisanin V, Bayraktar E, Kordelas L, Trenschel R, Ottinger H, Steckel NK, Tsachakis-Mück N, Leserer S, Ditschkowski M, et al. Optimizing anti-T-lymphocyte globuline dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies. Am J Transplant. 2019.

Fleischhauer K. Improved Accessibility of Optimally Matched Stem Cell Donors. Transplant Cell Ther. 2023;29(4):213-214.

Turki AT, Tsachakis-Mück N, Leserer S, Crivello P, Liebregts T, Betke L, Alashkar F, Leimkühler NBastian, Trilling M, Fleischhauer K, et al. Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG. Blood Adv. 2021.

Tsamadou C, Fürst D, Wang T, He N, Lee SJ, Spellman SR, Fleischhauer K, Hsu KC, Paczesny S, Verneris MR, et al. DONOR HLA-E STATUS ASSOCIATES WITH DISEASE FREE SURVIVAL AND TRANSPLANT RELATED MORTALITY AFTER NON IN VIVO T-CELL DEPLETED HSCT FOR ACUTE LEUKEMIA. Biol Blood Marrow Transplant. 2019.

Schetelig J, Baldauf H, Heidenreich F, Hoogenboom JD, Spellman SR, Kulagin A, Schroeder T, Sengeloev H, Dreger P, Forcade E, et al. Donor genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight. Front Immunol. 2024;15:1350470.

Weller JFrederic, Lengerke C, Finke J, Schetelig J, Platzbecker U, Einsele H, Schroeder T, Faul C, Stelljes M, Dreger P, et al. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study. Haematologica. 2023.